▲ Peaking
Business
Alzheimer’s brain decline slashed in half by ‘thrilling’ new twice-a-year drug: trial
Biogen's experimental tau-targeting drug Diranersen shows increasing clinical benefit at two years in early Alzheimer's disease, with coverage highlighting a twice-yearly dosing regimen.